BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.

ABSTRACT:

Background

This study aimed to determine whether the BRCA1 haplotype was associated with trabectedin efficacy in soft-tissue sarcoma (STS) patients.

Methods

We analysed BRCA1 single-nucleotide polymorphisms (SNPs) in tumour specimens from 135 advanced STS patients enrolled in published phase 2 trials or in a compassionate-use programme of trabectedin. Forty-four advanced STS patients treated with doxorubicin and 85 patients with localised STS served as controls. The 6-month nonprogression rate and overall survival (OS) were analysed according to BRCA1 haplotype using log-rank tests.

Results

A favourable BRCA1 haplotype (presence of at least one AAAG allele) was significantly associated with an improved 6-month nonprogression rate. It was the only variable significantl

SUBMITTER: Laroche-Clary A 

PROVIDER: S-EPMC4333490 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature